545 related articles for article (PubMed ID: 16886440)
1. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
Kurnatowski P; Makieło L; Horwatt-Bozyczko E
Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
3. [Susceptibility to miconazole and itraconazole of Candida strains isolated from hospitalized and outpatient clinic patients].
Kurnatowska AK; Kwaśniewska J
Wiad Parazytol; 2009; 55(4):415-23. PubMed ID: 20209818
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study.
Lamfon H; Porter SR; McCullough M; Pratten J
J Antimicrob Chemother; 2004 Feb; 53(2):383-5. PubMed ID: 14729749
[TBL] [Abstract][Full Text] [Related]
5. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
[TBL] [Abstract][Full Text] [Related]
6. Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates.
Naidu AS; Fowler RS; Martinez C; Chen J; Tulpinski J
J Reprod Med; 2004 Oct; 49(10):800-7. PubMed ID: 15568403
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Candida biofilms to histatin 5 and fluconazole.
Konopka K; Dorocka-Bobkowska B; Gebremedhin S; Düzgüneş N
Antonie Van Leeuwenhoek; 2010 May; 97(4):413-7. PubMed ID: 20140514
[TBL] [Abstract][Full Text] [Related]
8. Fungicidal effect of photodynamic therapy against fluconazole-resistant Candida albicans and Candida glabrata.
Dovigo LN; Pavarina AC; Mima EG; Giampaolo ET; Vergani CE; Bagnato VS
Mycoses; 2011 Mar; 54(2):123-30. PubMed ID: 19889173
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.
Paniagua GL; Monroy E; Negrete E; Vaca S
Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773
[TBL] [Abstract][Full Text] [Related]
11. Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance.
Ghannoum MA; Herbert J; Isham N
Mycoses; 2011 Jul; 54(4):e175-7. PubMed ID: 20236241
[TBL] [Abstract][Full Text] [Related]
12. Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal.
Khadka S; Sherchand JB; Pokhrel BM; Parajuli K; Mishra SK; Sharma S; Shah N; Kattel HP; Dhital S; Khatiwada S; Parajuli N; Pradhan M; Rijal BP
BMC Res Notes; 2017 Jun; 10(1):218. PubMed ID: 28646915
[TBL] [Abstract][Full Text] [Related]
13. Antifungal effect of high- and low-molecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-D-glucosamine against Candida albicans, Candida krusei and Candida glabrata.
Seyfarth F; Schliemann S; Elsner P; Hipler UC
Int J Pharm; 2008 Apr; 353(1-2):139-48. PubMed ID: 18164151
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activity of sertaconazole.
Drouhet E; Dupont B
Arzneimittelforschung; 1992 May; 42(5A):705-10. PubMed ID: 1627187
[TBL] [Abstract][Full Text] [Related]
15. [In vitro effect of itraconazole against various species of Candida].
Bastide M; Mallie M; Jouvert S; Montes B; Bastide JM
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):694-9. PubMed ID: 2552381
[TBL] [Abstract][Full Text] [Related]
16. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
17. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the CgPDR1 and CgERG11 genes in azole-resistant Candida glabrata clinical isolates from Slovakia.
Berila N; Borecka S; Dzugasova V; Bojnansky J; Subik J
Int J Antimicrob Agents; 2009 Jun; 33(6):574-8. PubMed ID: 19196495
[TBL] [Abstract][Full Text] [Related]
19. The role of antifungal susceptibility testing in the therapy of candidiasis.
Hospenthal DR; Murray CK; Rinaldi MG
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):153-60. PubMed ID: 15023422
[TBL] [Abstract][Full Text] [Related]
20. Candida albicans isolates from APECED patients show decreased susceptibility to miconazole.
Siikala E; Richardson M; Pfaller MA; Diekema DJ; Messer SA; Perheentupa J; Saxén H; Rautemaa R
Int J Antimicrob Agents; 2009 Dec; 34(6):607-9. PubMed ID: 19748230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
